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Summary
A discovery, synthesis and therapeutic application of cortisone present a paradigm for 
modern translational medicine (Hillier 2007, Saenger 2010), since they represented a joint 
achievement of discoveries by biochemists, Edward Calvin Kendall and Tadeus Reichstein; 
large scale synthesis by an industrial chemist, Lewis Hastings Sarett, and therapeutic appli-
cation by a rheumatologist, Philip Showalter Hench. The goal of translational medicine is to 
speed up the process between basic research and clinical practice, and to integrate multiple 
disciplines in order to understand diverse outcomes (Zhang et al. 2014). In this paper condi-
tions that made this basic/applied/clinical research interface possible will be presented: the 
rise of steroid chemistry, simultaneous individual accomplishments as well as continuous 
cooperation among scientists, military competitiveness, and cooperation among pharma-
ceutical companies. 
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Introduction
Since their first medical use in 1948 cortisone and its synthetic analogues 
have remained among the most widely prescribed medications in the world 
(Hillier 2007). Cortisone belongs to the group of steroid hormones of the ad-
renal cortex, first isolated in the 1930s by biochemist Edward Calvin Kendall 
in the USA and independently by Tadeus Reichstein in Switzerland at about 
the same time. Discovery, synthesis and therapeutic application of cortisone 
present a paradigm for modern translational medicine (Hillier 2007, Saenger 
2010), since they represented a joint achievement of discoveries by two bio-
chemists; large scale synthesis by an industrial chemist, Lewis Hastings Sarett, 
and therapeutic application by a rheumatologist, Philip Showalter Hench.1
The goal of translational medicine is to speed up the process between 
basic research and clinical practice, and to integrate multiple disciplines in 
order to understand diverse outcomes (Zhang et al. 2014).2 Translational re-
search is the dominant new strategy across the field of drug discovery that 
sets changes in the relationships between academies, biotechnological com-
panies, and pharmaceutical corporations (Fishburn 2013). Recently it has be-
come one of the most important areas of biomedicine because it facilitates 
laboratory discovery and therapeutic application, especially in the predic-
tion, prevention, diagnosis, and treatment of critical diseases (Zhang et al. 
2014). The discovery of cortisone turned out to have a medical, scientific and 
industrial importance, and it led to further discoveries with wider implica-
tions for drug development, such as conformational analysis3 (See Quirke 
2005, Slater 2000).
Steroids are employed as research materials in a wide range of research 
contexts, both in academic and industrial laboratories, also in biology and 
in chemistry (Slater 2000). They are a group of compounds with a common 
structure based on the steroid nucleus, consisting of three six-membered 
carbon rings and one five-membered carbon ring, which occur in plants and 
animals (Slater 2000). The general name steroid was introduced in 1936 to 
cover all compounds with a steroid-like skeleton. The sex steroids oestradiol, 
1 Stephen G. Hillier emphasized the paradigm label celebrating the Diamond Jubilee of 
the Society for Endocrinology in 2006 in the Jubilee Medal Lecture dedicated to the 
cortisone legacy, later published as the article “Diamonds are forever”, in the Journal of 
Endocrinology 195 (1).
2 Translational medicine, also known as translational science or translational research was 
introduced as “bench to bedside” by Dennis Choi in 1992, and first formally proposed in 
1996 (Zhang et al. 2014). 
3 Conformational analysis is a method for correlating steroid structures with the physical 
and chemical properties of the molecules. See Quirke 2005: 647, Slater 2000.
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testosterone and progesterone were discovered between 1929 and 1935. What 
followed is the discovery of adrenocortical hormones between 1935 and 1938 
(Hillier 2007). They were produced by partial synthesis, i.e. synthesis that be-
gan with structurally elaborate starting materials, complex natural products. 
A total synthesis referred to a synthesis starting from simple and inexpen-
sive materials whose composition was known, such as air and coal. Robert 
Burns Woodward achieved a total synthesis of cortisone in 1951 (Woodward 
et al. 1951). The discovery of cortisone and its therapeutic efficacy led to what 
Hillier (2007) called the “diamond decades” of steroid chemistry that started 
in the 1950s.
Cortisone success, however, is often described as a mixture of knowledge 
and luck. “A fascinating tale of good science, perseverance, and luck” which, 
as Burns says, “might not be possible in today’s regulatory environment” 
(2016:1), or a “discovery resulted from 19 years of imaginative and deductive 
observation together with an element of serendipity which seems to char-
acterise many fundamental discoveries” (Glyn 1998: 822). Leo Slater (2000) 
used cortisone research to show that the boundaries between the disciplines 
were flexible and the way the networks of research interpenetrated one an-
other. Several factors played a role in the cortisone case: the rise of steroid 
chemistry, simultaneous individual accomplishments as well as a continu-
ous cooperation among scientists, military competitiveness, and coopera-
tion among pharmaceutical companies. 
Kendall, Reichstein, and Hench
Edward Kendall at the Mayo Clinic in Rochester, Minnesota and Tadeus 
Reichstein at the Eidgenössische Technische Hochschule (ETH) in Zürich 
independently identified the structure of cortisone in the 1930s from extracts 
of bovine adrenal glands (Mason et al. 1936, Reichstein 1936). Kendall isolat-
ed eight crystalline cortical compounds from some 1.250.000 cattle carcass-
es, while Reichstein isolated twenty-eight crystalline compounds from the 
adrenals of 20.000 head of cattle (Shoppee 1956: 319-322). Reichstein estab-
lished his reputation with the synthesis of vitamin C in 1933, and Kendall 
had previously discovered thyroxin, a hormone of the thyroid gland, in 
1918 (Simoni et al. 2002). Kendall’s interest switched to the hormones of the 
adrenal cortex in 1929 when Albert Szent-György4 from Cambridge vis-
4 Albert Szent-Györgyi was awarded the Nobel Prize in Physiology or Medicine in 1937 for 
his discoveries in connection with the biological metabolic processes, with special referen-
ce to vitamin C and the catalysis of fumaric acid.
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ited Kendall at the Mayo Clinic. Szent Györgyi was at 
the time pursuing the isolation of vitamin C from ad-
renal glands. (See Quirke 2005: 648).
We learn that Kendall had the assistance of com-
mercial agreements and contracts with Parke-Davis 
in Detroit and Wilson Laboratories of the Wilson 
Packing Company of Chicago. Between 1934 and 1949 
they provided some 150 tons of adrenal glands for his re-
search. Kendall also produced about $9 million worth 
epinephrine, sold as Adrenalin, for Parke-Davis (Slater 
2000). Kendall’s program was a mixture of industrial process, chemical in-
vestigation, and basic medical research, being neither inherently pure nor 
applied. His work on the adrenals was expensive and laborious, and until the 
discovery of cortisone it seemed to be yielding no significant results. At the 
same time Reichstein worked with crude extracts provided by Organon, Inc. 
of Oss, Holland, not with adrenals (Slater 2000).5 Reichstein and Kendall in-
dependently assigned their new compounds letter designations; Reichstein’s 
“substance Fa” and Kendall’s “compound E” later proved to be identical, and 
Kendall named them cortisone in 1949 to avoid confusion with vitamin E.
Independent biochemical investigations were still 
far from discovering therapeutic efficacy. This was the 
accomplishment of Kendall’s colleague, Philip Hench, 
the head of the Department of Rheumatic Diseases at 
the Mayo Clinic. Hench hypothesised the presence of 
a therapeutic agent X that emerged in conditions of 
jaundice and pregnancy, and relieved arthritic patients 
from rheumatic symptoms (Hench 1964). His physio-
logic research of an unknown therapeutic agent began 
in 1929, and it took twenty years, until his announce-
ment at the Seventh International Congress of Rheumatology in New York 
in May 1949, to demonstrate that certain corticosteroids were able to reverse 
many of the acute manifestations of rheumatoid arthritis. Simultaneous dis-
coveries made identification of the features of cortisone possible. One was 
biochemical, related to the steroid structure of the hormones isolated from 
5 Reichstein also tried to use plant material as a starting point for the synthesis of corti-
sone. In 1947 two of his assistants went on an expedition to Africa to search for the seeds 
of Strophantus species, especially Strophantus sarmentosus. They spent nine months on the 
Gold Coast, Togo, the eastern Ivory Coast and Southern Nigeria collecting samples of 







the adrenal cortex, and the other was physiologic, related to therapeutic pos-
sibilities for rheumatic patients. The discovery of a biological therapeutic 
substance was undertaken in ignorance of its site of origin, relying solely on 
its function in the organism. Hench eliminated the possibility that agent X 
is a sex hormone, because patients of both sexes were relieved from arthritis 
pain with the occurrence of jaundice. Successful converging of the two dis-
coveries made at the same clinic presents the special serendipitous moment 
in the cortisone chronology. 
World War II
The outset of World War II played a significant role in the reinforcement 
of collaboration between scientists on the issue of adrenocortical hormones. 
In 1941, as the United States became involved in World War II, adrenal re-
search became an “internationally competitive effort” (Simoni et al. 2002: 
21). As Viviane Quirke notes: 
“The therapeutic potential of adrenal cortical hormones in rheumatic and 
other inflammatory diseases might never have been investigated, had it not 
been for the rumour in 1941 that Luftwaffe pilots were taking these hormones 
to increase their resistance to oxygen deprivation and be able to fly at higher 
altitudes.” (2005: 649) 
A German submarine was captured with cargo that was believed to be ad-
renal glands. A report saying that the Germans were buying adrenal glands 
from slaughterhouses in Argentina reached Washington (Slater 2000). It 
was later revealed that the cargo in the submarine was in fact liver for Otto 
Bayer’s work on vitamin B12 at IG Farbenindustrie (Quirke 2005).
It is true that steroids were being produced out of extracts of sex organs 
between 1920 and 1940 in Germany, but none of them was cortisone. The 
first European adrenal product was Doca (Deoxycorticosterone Acetate), a 
chemical sold by Swiss Ciba, identical to the later Cortiron, launched by the 
German Schering (Gaudillière 2013). Ciba became involved very early with 
steroid chemistry through its collaboration with the ETH in Zurich and later 
on with the University of Basel (Heusler, Kalvoda 1996). Ciba had an agree-
ment with ETH in Zürich, and therefore benefited from Reichstein’s work. 
All patent rights on steroids were assigned to Ciba. However, it was Schering 
that dominated the German drug market, and Dutch Organon which sup-
plied Reichstein with research material. So the three companies, Schering, 
Ciba, and Organon, signed an agreement in 1939 called Cortin, which or-
ganized and limited competition among these corporations, providing 
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important resources for circulation of research information and for mutual 
licensing of patents (Gaudillière 2013). Early uses of Schering’s Cortiron re-
mained limited because its usefulness was not clear, and cases of Addison’s 
disease, that it hoped to alleviate, were rare.6 That did not change during the 
war, even though steroids were given military priority because of their use 
in healing wounds (Gaudillière 2013). We can see how the boundaries be-
tween basic and applied were vague, and how European pharmaceutical and 
academic communities exchanged information and material, and facilitated 
intensive research. The line connecting ETH, Organon, Ciba, and Schering 
can be traced to the University of Basel in Switzerland, where Reichstein 
continued his work.
In America, a similar cooperation of industry and academics took place. 
The rumour about German usage of steroids motivated the American 
National Research Council to rank steroids at the top of wartime research 
agenda, above penicillin and antimalarials. Merck and the Mayo Clinic, 
as well as other academic and industrial groups, were collaborators in the 
steroid research program set up by the Office of Scientific Research and 
Development (OSRD), which intensified the research on adrenals and pro-
moted the crossings of disciplinary boundaries. (Slater 2000) It was also in 
1941 when the decision was brought to administer compound E (cortisone) to 
a patient. Hench and Kendall met at a conference, where Kendall remarked 
that his compound E increased the resistance of animals against reactions 
to typhoid vaccine. Hench made note of this in his pocket notebook, and 
eight years would elapse before there would be enough of this substance to 
administer to a rheumatoid patient (Hench 1964).
The priority of adrenal research was the reason why Lewis Sarett from 
Merck and Company worked for three months in Kendall’s laboratory in 
1942. The idea was to gain knowledge and return to Merck with a goal of de-
veloping large-scale synthetic methods for the compounds that were chosen 
for the initial studies, compounds A and E, because of their relative structur-
al simplicity. After several years funds waned as the effectiveness of the re-
search for various war-related uses did not meet the expectations. Eventually, 
only Kendall’s group at Mayo and his collaborators at Merck continued. By 
the end of the war, in 1945, enough compound A had been available for clin-
ical testing. It was a big disappointment it’s proven ineffectiveness in cases of 
Addison’s disease (Kendall 1964). 
6 Addison's disease is a chronic condition of adrenal insufficiency, deadly if not treated with 
hormone replacement therapy. 
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Synthesis and first supplies
Kendall and his associates pursued the research. Lewis Sarett synthe-
sised cortisone in 1946 in 37 steps at Merck (Sarett 1946). A partial synthe-
sis from desoxycholic acid that had been pioneered by Reichstein’s group 
in Basel produced the first 18 milligrams of cortisone. Shortly after the war 
ended Merck management decided to make cortisone available for clinical 
investigations. Jacob Van de Kamp, Max Tishler, along with Kendall, Sarett 
and Merck’s development staff improved Sarett’s partial synthesis, and 
by April 1948 sufficient amount of cortisone was available (Patchett 2002, 
Slater 2000). In September 1948 Philip Hench administered 100 milligrams 
of cortisone intramuscularly to a patient suffering from rheumatoid arthri-
tis.7It showed a rapid success in relieving pain and reducing inflammation. 
Subsequent trials with cortisone andadrenocorticotropic hormone (ACTH) 
gave similar symptomatic relief (Hench 1949, 1964).
The patent was assigned to the non-profit Research Corporation 
(Kendall 1964, Slater 2000). The Research Corporation had been founded in 
1912 partly to prevent the commercial exploitation of academic research. The 
Corporation held patents for scientists at universities and foundations and 
licensed these patents, producing income for the support of other research, 
and providing for the redistribution of research income (Slater 2000: 457-
458). In August 1949 the Committee of the National Academy of Sciences 
on the Investigation of Cortisone posed the problem of distributing the 
limited amount of cortisone. It was decided that the small amount available 
will be used only for clinical and experimental research and that it will be 
made available to selected investigators from the USA and Canada.Since the 
Academy had no funds with which to buy cortisone or to support research, 
it was 
“confidently expected that the needed funds will become available from 
both public and private sources. (...) The Academy committee has accepted 
this responsibility because of the deep conviction that a new discovery of the 
greatest importance to the health and welfare of countless people has been 
made and that it is vital to promote its most rapid and intelligent develop-
ment.” (Science, August 5, 1949) 
In the autumn of 1949the Research Corporation held the Cortisone 
Conference, where seventeen scientists to whom the Corporation provided 
support were invited (Slater 2000). Topics included a total synthesis, natural 
7 In 1950 cortisone started to be given by mouth, in the form of 100 mg tablets (BMJ 1 (4701) 
1951: 288). 
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raw materials for partial synthesis, hormone analogues, toxicity, and clinical 
testing. The second conference was held in Chicago in September 1950, and 
the third in New York in 1951.
We can say that the outbreak of World War II had a crucial role for the 
investments in adrenal research, understandable in the light of the emerging 
steroid research activity. Luckily enough, one of the compounds turned out 
to be physiologically active in a way no one could anticipate. However, the 
work on steroids had begun several decades earlier. Companies like Ciba, 
Schering, Organon, as well as French Roussel (Gaudillière 2013) industrial-
ized steroid research in the 1930s, including adrenal research, as we can see 
from Doca and Cortiron.
Kendall, Hench and Reichstein were awarded the 1950 Nobel Prize in 
Physiology or Medicine for their discoveries relating to the hormones of the 
adrenal cortex, their structure and biological effects. On November 1 1950, 
cortisone became available to physicians of the United States through drug 
supply houses. Merck’s brand of cortisone was named Cortone. The price 
was falling: In July 1949, the price per gram was $200.00. In 1950, it was re-
duced five times, from $150.00 in January to $35.00 on November 1 (Kendall 
1964: 276-277). However, in 1951 we can still read that cortisone “cannot yet, 
or perhaps ever, become a cheap medicament”. (BMJ 2 (4728) 1951: 406-408) 
This was mostly due to the lack of supplies of bile acid. Foreign sales were 
minimal, regulated by the US government, and were made primarily to 
those countries that would contribute the starting material, cattle bile, or 
participate in clinical development (Slater 2000: 467). 
Successes and controversies
Jean-Paul Gaudillière called cortisone “an iconic product of the ‘thera-
peutic revolution’” (2013: 190). Cortisone was used in treating excessive in-
flammation, allergy, acute infections, and autoimmune disorders. Eventually, 
it had a deep impact on several medical specialties, including ophthalmolo-
gy, gastroenterology, respiratory medicine, dermatology, nephrology, endo-
crinology and rheumatology. John H. Glyn, a British rheumatologist and 
Hench’s friend and colleague, wrote in 1998 that the discovery of cortisone 
transformed rheumatology from its “Cinderella status of the BC (before cor-
tisone) era” (1998: 823), though its clinical usefulness remained controversial. 
The dramatic effects in rheumatic patients and its anti-inflammatory agency 
were challenged by serious side effects brought on by high dosage levels and 
prolonged therapy (Beckett et al. 1956), as well as by relapse of the treated 
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condition once the treatment was ended (Wilson 1950, Carlisle 1950, Thorn 
1951). It was clear that “cortisone supresses rheumatoid arthritis but does not 
cure it” (BMJ 2(4725) 1951). It was discussed with caution, considered to be “a 
real danger if (…) it is used anything like as empirically by medical men gen-
erally as were the sulphonamides and penicillin” (Emery 1949). Glyn wrote 
in his memoire: 
“In the United States a black market developed which had serious medical 
and social repercussions. Patients who had experienced great relief of their 
symptoms were not prepared to relapse when supplies ran out. They became 
totally dependent on the drug. Overdosage led to devastating side effects, 
and the ever escalating cost of maintaining their supplies resulted all too 
often in financial destitution. Such patients had no alternative but to seek 
relief by registering as guinea pigs to research groups such as the one at the 
Bellevue Hospital in New York which I joined in 1952.” (1998: 823)
Alternative sources of starting material and new methods of produc-
tion were investigated because of shortages of bile acids and of money (BMJ 
1(4668) 1950: 1477-1478). Kendall reported at the American Chemical Society 
meeting that 40 head of cattle were needed to provide cortisone needed daily 
by one patient(The Science News-Letter 57(8) 1950: 120-121).Merck officials-
expected the production to be tripled or quadrupled by the middle of 1952. 
(The Science News-Letter 59 (11) 1951: 168-169) The increased output was 
expected from recently investigated botanical sources as well as from total 
synthesis.
John Glyn led the first UK cortisone studies. Small quantities of corti-
sone and ACTH were distributed to hospitals in Britain (BMJ 2 (4693) 1950: 
1375). Hench gave two well attended lectures in London in 1950 (BMJ 2 (4693) 
1950: 1375), and Glyn published the preliminary results in the British Medical 
Journal in 1950 (Copeman et al. 1950), and the next in 1952 (Copeman et al. 
1952). In 1954 the results of the first multi-centre crossover trial of cortisone 
and aspirin organised by the British Nuffield Foundation and the Medical 
Research Council were published in the British Medical Journal.8 The tri-
al concluded that there was no evident difference between the two groups. 
This led to a sharp correspondence between Glyn and Austin Bradford-Hill, 
who designed the trial (Glyn, Todd 1954, Bradford-Hill 1954). Glyn criticized 
the design, the selection of patients, and the dosage: 
8 The trial was organised in six centres and included 61 patients with rheumatoid arthritis 
(BMJ 1 (4873) 1954: 1223–27).
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“My comments on this trial are largely a text on which to hang a plea to the 
statisticians to modify their rigid approach to clinical trials. Perfect statisti-
cal techniques are not possible when dealing with biological material, nor is 
it possible at the early stage at which the Medical Research Council generally 
formulate their trials for them to lay down the optimum regimes which are 
not liable to subsequent criticism. (…) In other words, the pendulum away 
from therapeutic empiricism has swung too far.” (Glyn, Todd 1954: 1376-1377) 
We learn that in the later years, in a personal conversation, Bradford-
Hill “graciously agreed” that some of Glyn’s comments “were justified in 
the light of subsequent events” (Glyn 1998: 823).Sir Austin Bradford-Hill 
was an English epidemiologist and statistician who pioneered randomized 
control trials and established a criterion of causation (Bradford-Hill criteria 
of causation). Randomized control trials have been the cornerstone of evi-
dence-based practice since then. They established the procedure and domi-
nate delivery of health care. Their critics focus on the problems of statistical 
inference and generalisability of population-based research findings to par-
ticular instances of clinical decision-making. Evidence-based practice has 
been accused for being de-personalised, and the person-centred approach 
has recently gained new attention (see Anjum et al. 2015). Similar reluctance 
and criticism can be traced in Glyn’s 1954 letter to Bradford-Hill. Cortisone 
brought additional awareness of a need for individualised therapy and pa-
tient approach.
By 1955, analogues with reduced toxicity and enhanced physiological ac-
tivity were developed (BMJ 1 (4929) 1955: 1520). Though Kendall believed it 
“highly improbable” (1964: 278) that any product would occur that would be 
used in the place of cortisone and cortisol, generic formulations of predni-
sone, prednisolone (see Jenkins, Sampson 1967) and dexamethasone remain 
in widespread use to this day. In chemistry, a development of the method 
of conformational analysis facilitated the study of the relationship between 
structure and activity, providing a more rational approach to drug design 
(Quirke 2005). In medicine and pharmacology cortisone was an important 
incentive for a new attention to chronic diseases that occurred in the post-
war research (Quirke 2005). It is now known that intracrine9 metabolism of 
cortisone to cortisol sustains local amplification of glucocorticoid action at 
sites of inflammation throughout the body (Hillier 2007).10
9 “Intracrine” denotes a type of hormone function in which a regulatory factor acts wit-
hin the cell that synthesizes it by binding to intracellular receptors. (Dorland’s Medical 
Dictionary for Health Consumers 2007)
10 Cortisol is the closely related compound F, in Kendall's notation. 
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Conclusion
The aim of this paper was to expose a fragment of the history of adre-
nocortical steroid research. The case of adrenal research between 1930s 
and 1950s shows the evident cooperation between academic and industrial 
in both European and American research activity (ETH-Ciba-University 
of Basel, Ciba-Shering-Organon, Mayo-Merck). Adrenal steroid research 
was expensive and depended on the providers of research material, such 
as Organon, Parke-Davis, and Merck Company. A continuous cooperation 
between scientists generated intense exchange of hypothesis and material, 
which led to both fundamental and practical achievements. Cooperation be-
tween pharmaceutical companies (the Cortin agreement) and non-profit or-
ganisations (the Research Corporation) provided a stabile drug market and 
sound research climate through licensing of patents and exploitation of new 
drugs. We have also seen the way political circumstances created research 
priorities and the way wartime posed time-constraints on achieving research 
goals, which intensified research activity.
Note: This paper is supported by the European Social Fund of the European 
Union as a part of the Operational Programme “Human Resources Development” 
through the funding of research project HR.3.2.01-0350 “Building a support system 
for young researchers”. 
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Sažetak
Otkriće, sinteza i terapijska primjena kortizona predstavljaju paradigmu moderne tran-
slacijske medicine (Hillier 2007, Saenger 2010) jer združuju otkrića biokemičara Edwarda 
Calvina Kendalla i Tadeusa Reichsteina; otkriće kemijske sinteze za široku primjenu in-
dustrijskog kemičara Lewisa Hastingsa Saretta i otkriće terapijske primjene reumatologa 
Philipa Showaltera Hencha. Cilj je translacijske medicine ubrzati proces između bazičnog 
istraživanja i kliničke prakse te integrirati različite discipline da bi se razumjeli različiti is-
hodi (Zhang et al. 2014). U ovome radu predstavit ću uvjete koji su omogućili ovu suradnju 
bazičnog, primijenjenog i kliničkog istraživanja: uspon steroidne kemije, istovremena pojedi-
načna dostignuća, kao i kontinuirana suradnja između znanstvenika, vojna kompetitivnost 
i suradnja između farmaceutskih kompanija.
Key words: kortizon; translacijska medicina; Edward Kendall; Philip Hench; društveni 
aspekti farmakologije.
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